GlassScriptPhysician profile
Dale L Coy
NPI 1770578858
$8,877.09
in general payments reported to CMS, 2019-2025
36 companies · $2,355 in 2025
The $2,355 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,538 · 2020: $239 · 2021: $156 · 2022: $1,075 · 2023: $1,728 · 2024: $1,786 · 2025: $2,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,690 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,689.67 |
| Education | $178.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,890.05 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,121.02 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $754.95 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $510.15 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.70 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $406.46 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $371.34 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $358.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $317.12 | 2019-2025 | Ocaliva |
| Pfizer INC. | $306.71 | 2019-2025 | |
| Genzyme Corporation | $255.27 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $248.53 | 2024-2025 | Iqirvo |
| Ardelyx, INC. | $180.72 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $165.21 | 2019-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $136.63 | 2024-2025 | Vegzelma, Zymfentra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $130.25 | 2019-2025 | Sutab, Suflave |
| Lilly USA, LLC | $121.49 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $115.57 | 2019-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $110.78 | 2024-2025 | Voquezna |
| Vivus LLC | $105.12 | 2023-2025 | Pancreaze |
| Nestle Healthcare Nutrition INC. | $91.38 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $70.29 | 2022-2024 | Linzess |
| Mirum Pharmaceuticals, INC. | $70.16 | 2025 | Livmarli |
| Evoke Pharma, INC. | $69.58 | 2022-2025 | |
| Romark Laboratories, Lc | $69.20 | 2019-2020 | |
| Biocon Biologics INC | $69.06 | 2023-2025 | Yesintek, Hulio |
| Aimmune Therapeutics, INC. | $60.46 | 2024 | |
| Ucb, INC. | $59.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.64 | 2022-2024 | Dificid |
| Allergan, INC. | $40.77 | 2019 | |
| Concordia Pharmaceuticals INC. | $21.10 | 2019 | |
| Dova Pharmaceuticals | $19.05 | 2019 | |
| Organon LLC | $17.79 | 2023 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.64 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $16.94 | 2023 | Idacio |
| Sandoz INC. | $16.20 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Coy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.